anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in the movement breaks every 30 minutes group complete a 7-day baseline period, followed by 2 weeks of the selected dose condition. Participants are asked to complete movement breaks every 30 minutes during all waking hours on weekdays and weekends (i.e. 7 days a week). Information regarding work productivity, energy and fatigue levels, mood, physical activity, and barriers/facilitators to taking movement breaks are collected via either 5 daily SMS surveys throughout the day (9am, 12pm, 3pm, 6pm, 9pm) or one emailed survey at the end of each day (8pm). Survey delivery method is randomized. Participants also provide feedback regarding the feasibility, acceptability, and appropriateness of the intervention.
The invention mainly relates to the technical field of cosmetics, and discloses garlicin hand cream. The garlicin hand cream is made from the following raw materials, garlic, garcinia pedunculata, citronella grass, peach blossoms, gomphrena globosa, tea oil, linseed oil, glycerin, white granulated sugar, lactic acid bacteria, soya lecithin and spices. The garlicin hand cream is simple in method, full in fragrance, and is moistening while not oily. Garlic is subjected to low-temperature refrigeration, fermentation and extraction, so that garlicin is protected from decomposition, the garlic odor is reduced, the conversion rate of alliin is improved, and the content of garlicin is increased. The extraction rate of garlicin can reach 0.503%, and the purity can reach 20.4%. Multiple Chinese herbal medicines and plant spices are added to cooperate with garlicin, so that the hand cream is antibacterial and anti-inflammatory, can prompt blood circulation, restore damaged tissues, prevent and treat chilblain, and soften the skin. Through addition of multiple oil components, the hand cream can be used after heating and cooling, is moistening while not oily, and is effectively moistening. After homogenization, the hand cream is uniform and fine, is easy to be absorbed and free of any additive, and is safe and healthy. The sales volume of the hand cream can be increased by 17.4%, and the economic income can be improved by 18.9%.
The resting control training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to schedule regular rest periods as a means of deliberately retreating from the activities of the day. Length and frequency of the rest periods mirrored the time demands of the meditation training. Participants received a plausible rationale for the control training that linked acute depression to stress and suggested rest, relaxation, and disengagement from negative thinking as an initial and preliminary step towards recovery.
BACKGROUND: Amniotic banding is a rare condition that can lead to structural limb anomalies, fetal distress and adverse obstetric outcomes. The main hypothesis for its etiology is a rupture of the amniotic membrane in early pregnancy, with the formation of tightly entangling strands around the fetus. These strands can constrict, incise, and subsequently amputate limb parts, the neck or head. More rarely, the amniotic banding can affect the umbilical cord, leading to fetal distress or potential intra-uterine fetal demise.
OBJECTIVE: We present a unique case of a 26-week pregnant woman who attended a polyclinical consultation due to reduced fetal movements with concerning cardiotocography (CTG) findings. A review of the literature about amniotic banding of the umbilical cord was conducted as well, identifying diagnostic and interventional options for the obstetrician's practice.
STUDY DESIGN: This is a case report, alongside a review of the literature.
RESULTS: The CTG indicated fetal distress, prompting an emergency caesarean section (C-section). Upon delivery, the neonate exhibited signs of amniotic band sequence, with distal phalangeal defects on the right hand and severe constriction of the umbilical cord caused by amniotic strands, the latter precipitating fetal hypoxia. Direct ultrasound diagnosis remains a challenge in the absence of limb amputation, yet indirect signs such as distal limb or umbilical doppler flow abnormalities and distal limb edema may be suggestive of amniotic banding. MRI is proposed as an adjuvant diagnostic tool yet does not present a higher detection rate compared to ultrasound. Fetoscopic surgery to perform lysis of the amniotic strands with favorable outcome has been described in literature.
CONCLUSION: This case presents the first reported survival of an extremely preterm fetus in hypoxic distress as a cause of amniotic banding of the umbilical cord, with a rare degree of incidental timing. Ultrasound diagnosis remains the gold standard. Obstetrical vigilance is warranted, with fetal rescue proven to be feasible.
Fusarium solani exerts detrimental effects on plant growth, which is one of the reasons for the incidence of apple replant disease. Arbuscular mycorrhizal fungi (AMF) enhance plant resistance to Fusarium wilt; however, the mechanism remains poorly understood. Therefore, the present study investigated the symbiosis between apple and AMF and explored the physiology, especially nitrate metabolism, antioxidant defense, and photosynthetic performance, when infected by F. solani. The experiment was carried out with four treatments, namely -AMF - F. solani, -AMF + F. solani, -AMF + F. solani, and + AMF + F. solani. In this study, the -AMF + F. solani treatment increased the activity of enzymes associated with nitrogen metabolism, such as the nitrate and nitrite reductases, in the apple root system. The +AMF + F. solani treatment showed higher antioxidant enzyme activities than the -AMF + F. solani by F. solani infection. The apple seedlings of the +AMF + F. solani treatment decreased reactive oxygen accumulation and reduced the oxidative damages triggered by F. solani infection. The improvement in antioxidant capacity due to the +AMF + F. solani treatment was closely associated with the upregulation of genes related to the antioxidant system. The F. solani infection greatly damaged the photosynthetic process, while the +AMF + F. solani treatment significantly improved it compared to the -AMF + F. solani treatment. In conclusion, the study demonstrated that the apple-AMF symbiosis plays an active role in regulating the resistance against F. solani infection by enhancing defense response and nitrogen metabolism.
This is a Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease. 51 patients were enrolled. All patients have previously banked their own mesenchymal stem cells at Hope Biosciences. Eligible participants are either 65 years of age or older, have preexisting conditions, or are at high exposure risk of contracting COVID-19. The primary objective of this study is to provide immune support against COVID-19, measured by the presence or absence of adverse events and serious adverse events related to the study drug. In addition, participants will be monitored for overall clinical status by standard clinical laboratories and inflammatory markers. Participants will complete Short Form Health Survey (SF-36) and depression module (PHQ-9) questionnaires.
FIELD: chemistry.SUBSTANCE: present invention relates to a method of producing a cross-linked amino-containing polymer, as well as to a cross-linked amino-containing polymer. Said method involves cross-linking a preformed amine polymer in a reaction mixture to form a cross-linked amine polymer. Reaction mixture contains a pre-formed amine polymer, a solvent, a crosslinking agent and a swelling agent for the preformed amine polymer. Pre-formed amine polymer has an absorption capacity of the swelling agent. Amount of the swelling agent in the reaction mixture is lower than the capacity of absorption of the swelling agent which the previously obtained amine-containing polymer has. Weight ratio of the swelling agent to the pre-formed amine-containing polymer in the reaction mixture is 1:1. Solvent is introduced at the crosslinking step to disperse the pre-formed cross-linked polymer grains.EFFECT: obtained polymer has the ability to remove protons and chloride ions from the gastrointestinal tract in an animal, including a human.25 cl, 6 dwg, 32 tbl, 10 ex
PURPOSE: Food additive is provided to be effective against wrinkle by controlling factors related to production and decomposition of collagen. CONSTITUTION: Food additive comprises processed extract of Panax species plant as an active ingredient that let sum of contents of ginsenoside Rg3, Rg5, and Rk1 higher than sum of content of ginsenoside Rb1, Rb2, Rc, and Rd. Processed Panax genus ginseng extract is manufactured as follows. Panax species plant is sliced and put in an autoclave to be heated at 70 °C to 150 °C, under 2 to 30 atmospheric pressure for 1 to 24 hours. Heated material is 1 or 20 times weight ratio(w/w) of water of sample weight, or low grade alcohol of C1 to C4 or mixture of these using cold extraction, hot water extraction, ultrasonic wave extraction, reflux cooling extraction, or heating extraction to be extracted. Extract is filtered, concentrated under reduced pressure, and dried. Food types are confectionery, pastry, ice cream products, tea, fermented milk products like yogurt, dairy products, seasoning, liquor, canned food, or bottling, noodles, processed livestock products, processed marine products, fermented microorganism products, soya products, grain products, processed meat products, licorice products, or herb products.
BACKGROUND: Surgical site infections (SSIs) are a common and potentially preventable complication of lower limb revascularization surgery associated with increased healthcare resource utilization and patient morbidity. We conducted a systematic review to evaluate multivariable prediction models designed to forecast risk of SSI development after these procedures.
METHODS: After protocol registration (CRD42022331292), we searched MEDLINE, EMBASE, CENTRAL, and Evidence-Based Medicine Reviews (inception to April 4th, 2023) for studies describing multivariable prediction models designed to forecast risk of SSI in adults after lower limb revascularization surgery. Two investigators independently screened abstracts and full-text articles, extracted data, and assessed risk of bias. A narrative synthesis was performed to summarize predictors included in the models and their calibration and discrimination, validation status, and clinical applicability.
RESULTS: Among the 6,671 citations identified, we included 5 studies (n = 23,063 patients). The included studies described 5 unique multivariable prediction models generated through forward selection, backward selection, or Akaike Information Criterion-based methods. Two models were designed to predict any SSI and 3 Szyilagyi grade II (extending into subcutaneous tissue) SSI. Across the 5 models, 18 adjusted predictors (10 of which were preoperative, 3 intraoperative, and 5 postoperative) significantly predicted any SSI and 14 adjusted predictors significantly predict Szilagyi grade II SSI. Female sex, obesity, and chronic obstructive pulmonary disease significantly predicted SSI in more than one model. All models had a "good fit" according to the Hosmer-Lemeshow test (P > 0.05). Model discrimination was quantified using the area under the curve, which ranged from 0.66 to 0.75 across models. Two models were internally validated using non-exhaustive twofold cross-validation and bootstrap resampling. No model was externally validated. Three studies had a high overall risk of bias according to the Prediction model Risk Of Bias ASsessment Tool (PROBAST).
CONCLUSIONS: Five multivariable prediction models with moderate discrimination have been developed to forecast risk of SSI development after lower limb revascularization surgery. Given the frequency and consequences of SSI after these procedures, development and external validation of novel prediction models and comparison of these models to the existing models evaluated in this systematic review is warranted.
Pain after cesarean section is usually associated with incision site and uterine contractions. There are various medical treatment and midwifery applications for the resolution of pain and gas output after cesarean section. Recently, it has been stated that in addition to the treatments applied after surgery, non-drug methods should be used to increase the effectiveness of recovery. These methods include applications such as hot application, abdominal massage, music therapy, chewing gum. The effect of hot application in patients with post-operative gas problems is the acupuncture points of the foot, warm and moist heat stimulation and the small intestine, colon, anus and other reflective areas. activates blood circulation. It is predicted that postpartum comfort will increase in the postpartum postpartum, whose pain decreases with postpartum heat application and intestinal mobility returns to normal. The aim of this study is to determine the effect of applying heat to the feet after cesarean section on postpartum comfort, pain and gas output.
Thoracic manipulation T1-T5 if somatic dysfunction. Intrathoracic fascia stretch x 3. Recoil sternum x 3. Cranial base release - 4 steps.
PURPOSE:To provide a dental composition capable of giving an excellent hardened product and composed of a vinyl compound and an organic composite filler produced by polymerizing a carboxylic acid monomer and a vinyl monomer in a polymerization system dispersed with an inorganic compound in the presence of a radical polymerization initiator. CONSTITUTION:The objective dental composition is composed of a vinyl compound and an organic composite filler produced by polymerizing a carboxylic acid monomer of formula I [R1 and R2 are H, alkyl, COOY (Y is H, NH4 or alkali metal), halogen, phenyl, etc.; R3 is H, alkyl, halogen, phenyl, etc.: X is H, NH4 or alkali metal atom] or formula II (R4 and R5 are H, alkyl, halogen, phenyl, etc.) (e.g. acrylic acid, crotonic acid, etc.) and a vinyl monomer in a polymerization system dispersed with an inorganic compound (e.g. barium sulfate, SiO2, etc.) in the presence of a radical polymerization initiator (e.g. benzoyl peroxide). Since the filler is firmly integrated in the composition, the obtained cured material has high mechanical properties and excellent appearance.
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to development of complex agents used for treatment of patients with disorders of lipid metabolism. Proposed agent has Graphites C6, Hydrastis canadensis C3, Fucus vesiculosus C3, Phytolacca americana C3, Carbo vegetabilis C6, Prunus spinosa C3 and all components are taken at equal parts. Proposed agent can be made as sugar granules. Agent provides the normalization of total metabolism, patients show increased motility, working capacity, improvement of state of health. EFFECT: enhanced effectiveness of agent. 2 cl, 1 ex
The present invention provided a use of Bacillus amyloliquefaciens composition for preventing or improving hyperlipidemia and related diseases. The deposit number of the strain is BCRC 910784, which was deposited at the Food Industry Research and Development Institute in Hsinchu, Taiwan. The deposit date is July 4, 2017. The strain inhibits the synthesis of cholesterol and promotes the utilization and excretion of cholesterol so that the strain can reduce serum total cholesterol, triglyceride, low-density lipoprotein, very low-density lipoprotein and low-density lipoprotein/high-density lipoprotein ratio, and increase serum high-density lipoprotein, etc. to regulate blood lipids. Moreover, the strain can reduce liver triglyceride, etc., thereby improving fatty liver and controlling body fat.
A cluster of genes involved in the synthesis and/or addition of oleandrose to avermectin aglycones has been cloned. A 11-kb PstI clone complemented 28 avermectin glycosylation mutants in seven complementation classes. Sequencing of an 10-kb region identified 9 ORFs and an additional partial ORF. Eight of the ORFs were correlated to the seven glycosylation complementation classes. Sequence comparison to Genbank databases identified 6 genes: dTDP-glucose synthase; dTDP-glucose 4,6 dehydrase; dTDP-4-keto-hexose reductase; dTDP-hexose 3,5 epimerase; dTDP-hexose 3' O-methylase; and an avermectin aglycone-dTDP-oleandrose glycosyltransferase. The ninth ORF was essential for biosynthesis of the avermectin aglycones. The partial ORF encoded part of an avermectin polyketide synthase module 7.
Adoptive cell therapy has been previously shown to be an effective treatment option for patients with melanoma. Due to an immunosuppressive microenvironment, not all patients respond to this therapy. In this trial, the immune suppressive microenvironment will be targeted by adding a PD-1 blocking antibody in combination with a TIL Transfer. Tumor-infiltrating lymphocytes will be expanded from resected melanoma samples from the patient and expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.
Emicizumab is approved for prophylaxis of patients with hemophilia A (HA). Despite its efficacy in reducing bleeding, some patients on emicizumab still experience hemarthrosis, but no tool is yet available to identify those at a higher risk of spontaneous joint bleeding. This study aimed to evaluate whether laboratory measurements (global coagulation assays and emicizumab concentration) and/or arthropathy scores can distinguish patients at higher risk of spontaneous joint bleeding while on emicizumab prophylaxis. A thrombin generation assay was performed upon the addition of tissue factor and synthetic phospholipids. Nonactivated thromboelastography was performed on citrated whole blood. Emicizumab concentrations were measured using a modified 1-stage factor VIII assay. The degree of hemophilic arthropathy was assessed using the Hemophilia Joint Health Score and Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score. A Cox proportional hazards model was used to evaluate the association between variables and bleeding. The predictive power of these variables was investigated using receiver operating characteristic (ROC) analysis. Forty patients with severe HA, with or without inhibitors, on emicizumab prophylaxis were enrolled in an observational cohort study. Ten of 40 developed spontaneous joint bleeding. None of the laboratory parameters were able to distinguish patients with a higher risk of spontaneous joint bleeding. ROC analysis showed that during emicizumab prophylaxis, only the presence of synovitis and a higher HEAD-US score were associated with spontaneous joint bleeding (area under the curve, 0.84). A greater degree of arthropathy and the presence of synovitis could help predict the risk of spontaneous joint bleeding in patients with HA on emicizumab prophylaxis.
Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq.) up to 525 mg eq. based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
Acute pain management requires balancing analgesia with adverse effects risk. The voltage-gated sodium channel NaV1.8 plays an important role in pain physiology, and its inhibition was shown to have analgesic effects. VX-548 is a new oral NaV1.8-specific inhibitor that received United States Food and Drug Administration Fast Track and Breakthrough Therapy designations. Its efficacy was demonstrated in two Phase II trials of patients who underwent abdominoplasty and bunionectomy. These showed that VX-548, when given as an oral loading dose of 100 mg followed by 50 mg 12-hly, significantly decreased pain scores compared with placebo. Similarly, two Phase III trials of patients who underwent abdominoplasty and bunionectomy comparing VX-548 with hydrocodone bitartrate-acetaminophen and placebo reported significantly reduced pain scores compared with placebo, but no improvement compared with hydrocodone bitartrate-acetaminophen. Evidence from Phase II and III trials suggest that VX-548 is well-tolerated, with headache, nausea, constipation and dizziness being the most common adverse effects. However, the safety of prolonged VX-548 administration is uncertain; a Phase II trial of patients with diabetic neuropathy who received high-dose VX-548 over 12 weeks reported decreased creatinine clearance. Data pertaining to VX-548 safety and efficacy within the context of multimodal analgesia and pregnancy are also needed.
Ciclopirox Topical Solution, 8% (Nail Lacquer) contains a synthetic antifungal agent, ciclopirox. It is intended for topical use on fingernails and toenails and immediately adjacent skin.

Each gram of Ciclopirox Topical Solution, 8% (Nail Lacquer) contains 80 mg ciclopirox in a solution base consisting of ethyl acetate, NF; isopropyl alcohol, USP; and butyl monoester of poly[methylvinyl ether/maleic acid] in isopropyl alcohol. Ethyl acetate and isopropyl alcohol are solvents that vaporize after application.

Ciclopirox Topical Solution, 8% (Nail Lacquer) is a clear, colorless to slightly yellowish solution.

The chemical name for ciclopirox is 6-cyclohexyl- 1-hydroxy-4-methyl-2(1H)- pyridone, with the molecular formula C12H17NO2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:
Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb \<8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
Participants will be recruited to this one-time assessment during their follow-up visits. After completing a consent procedure specific to this study component, participants will be provided with instructions on how to fully self-administer the procedure of a finger stick and also blotting to collect a blood specimen using a 1, 3 or 5 blood spot specimen collection card. These specimens will be labeled with the participant's unique identification number, and no other identifying information. The dried blood spots will be evaluated by a laboratorian to assess quality, but will not be tested for HIV. This evaluation will help determine what number of self-collected dried blood spots yields the highest usable quantity of sample for HIV testing. There will be a separate monetary incentive of $30 for this procedure.